Envision (H-51766)

This is a randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab (BIIB037) in participants with Alzheimer’s disease.

Basic eligibility criteria:

• Ages 60-85
• Amnestic MCI or early AD.  MMSE>=22
• Cannot be on anticoagulation or have significant vascular disease on brain MRI
• No serious medical conditions that would limit study participation